{"symbol": "CGIX", "name": "Cancer Genetics", "next_earnings_utc": 1591610400, "next_earnings_period_start_date_utc": 1585612800, "next_earnings_period_end_date_utc": 1585612800, "next_earnings_has_time": true, "next_earnings_name": "2020 Q1", "next_earnings_year": 2020, "next_earnings_quarter": 1, "next_earnings_revenue_num_analysts": null, "next_earnings_revenue_consensus": 10769000.0, "next_earnings_eps_num_analysts": null, "next_earnings_eps_consensus": null, "eps_up_revisions": null, "eps_down_revisions": null, "revenue_up_revisions": null, "revenue_down_revisions": null, "total_analysts": 0, "analysts_sell": null, "analysts_buy": null, "analysts_outperform": null, "analysts_hold": null, "analysts_underperform": null, "webpage": "cancergenetics.com", "year_founded": 1999, "street_address": "Meadows Office Complex", "city": "Rutherford", "state": "NJ", "zipcode": "07070", "country": "United States", "phone_number": "201-528-9200", "short_description": "Cancer Genetics, Inc., through its subsidiary, vivoPharm, Pty Ltd., provides contract research services primarily focusing on studies to guide drug discovery and development programs in the oncology and immuno-oncology fields in the United States, Europe, and the Asia Pacific.", "long_description": "Cancer Genetics, Inc., through its subsidiary, vivoPharm, Pty Ltd., provides contract research services primarily focusing on studies to guide drug discovery and development programs in the oncology and immuno-oncology fields in the United States, Europe, and the Asia Pacific. Its clinical offerings include a portfolio of proprietary tests, such as comparative genomic hybridization microarrays and next generation sequencing panels, gene expression tests, and DNA fluorescent in situ hybridization probes targeting hematological, urogenital, and HPV-associated cancers, in conjunction with ancillary non-proprietary tests. The company also offers a range of non-proprietary oncology-focused tests and laboratory services to oncologists and pathologists at hospitals, cancer centers, and physician offices, as well as biotech and pharmaceutical companies to support their clinical trials. Cancer Genetics, Inc. was founded in 1999 and is based in Rutherford, New Jersey.", "industry_name": "Biotechnology", "sector_name": "Health Care", "is_defunct": false, "exchange": "NASDAQ", "equity_type": "stocks", "market_cap": 6488348, "total_enterprise": 8558348, "number_of_employees": 159, "outstanding_shares": 2099789, "eps": -6.289968, "diluted_eps": -6.348821, "earnings_from_cont_operations": -24364000, "gross_profit": 10433000, "cash": 2147000, "total_debt": 4217000, "total_revenue": 29643000, "cash_from_operations": -6652000, "net_income": -10180000, "ebitda": -13674000, "year_low_stock_price": 1.92, "year_high_stock_price": 9.5, "seekingalpha_follower_count": 4946, "image_url": "https://raw.githubusercontent.com/earnbros/earnbros.github.io/master/api/images/companies/CGIX.png"}